董事介绍
注:董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Mastrototaro | 男 | Chief Operating Officer and Director | 65 | 50.20万美元 | 9.71 | 2026-04-28 |
| Rubén Caballero | 男 | Director | 58 | 11.34万美元 | 2.62 | 2026-04-28 |
| Brian Cullinan | 男 | Director | 66 | 16.73万美元 | 3.81 | 2026-04-28 |
| Emily Wang Fairbairn | 女 | Chair of the Board and Director | 64 | 25.36万美元 | 9.52 | 2026-04-28 |
| Seth Demsey | 男 | Director | 49 | 50.00万美元 | 未持股 | 2026-04-28 |
高管介绍
注:高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Mastrototaro | 男 | Chief Operating Officer and Director | 65 | 50.20万美元 | 9.71 | 2026-04-28 |
| Jeremy Cogan | 男 | Chief Financial Officer | 57 | 52.80万美元 | 8.89 | 2026-04-28 |
| Jay Crystal | 男 | Chief Executive Officer | 48 | 50.00万美元 | 未持股 | 2026-04-28 |
董事简历
中英对照 |  中文 |  英文- John Mastrototaro
-
John Mastrototaro自2020年12月起担任公司董事,并同意不迟于2021年4月1日成为我们的总裁兼首席执行官。Mastrototaro先生在医疗器械行业拥有超过30年的经验,领导创新并将新产品推向市场。Mastrototaro先生自2017年以来一直担任Orthosensor,Inc.的首席运营官。此前,Mastrototaro先生在Medtronic,plc.和Minimed,Inc.度过了职业生涯的大部分时间,在那里他在发起和领导糖尿病世界的一系列第一方面发挥了重要作用,包括动态连续血糖监测系统,该传感器增强了胰岛素泵和早期人工胰腺。在加入Orthosensor之前,Mastrototaro先生于2013年至2017年担任美敦力(Medtronic&8217;)的首位信息学副总裁,他在该职位上帮助制定了一项利用数据和分析改善梦百合交付的企业战略。在Medtronic&8217;s Diabetes Division任职期间,Mastrototaro先生担任多个职位,包括CTO,研发与业务发展副总裁和临床研究与健康事务全球副总裁。Mastrototaro先生的职业生涯始于礼来公司(Eli Lilly)。他持有Holy Cross College的数学和物理学士学位,以及Duke University的生物医学工程硕士和博士学位。Mastrototaro先生撰写了超过50篇同行评议的手稿,并拥有超过60项美国专利。
John Mastrototaro has served as Chief Operating Officer of the Company since March 30, 2026. Previously, Mr. Mastrototaro served as President and CEO from April 2021 to March 30, 2026. Mr. Mastrototaro has over 30 years of experience in the medical device industry, leading innovation and bringing new products to the market. Mr. Mastrototaro served as the Chief Operating Officer of Orthosensor, Inc. from 2017 to March 2021. Previously, Mr. Mastrototaro spent the majority of his career with Medtronic, PLC. and MiniMed, Inc., where he was instrumental in initiating and leading a series of firsts in the world of diabetes, including the ambulatory continuous glucose monitoring system, the sensor augmented insulin pump and the early generations of the artificial pancreas. Prior to joining Orthosensor, Mr. Mastrototaro was Medtronic's first VP of Informatics from 2013 to 2017, a role in which he helped develop a corporate strategy for the use of data and analytics to improve healthcare delivery. During his tenure in Medtronic's Diabetes division, Mr. Mastrototaro held a number of positions, including CTO, VP of R&D and Business Development and Global VP of Clinical Research and Health Affairs. Mr. Mastrototaro started his career with Eli Lilly. He holds a B.A. in Mathematics and Physics from Holy Cross College and M.S. and Ph.D. in Biomedical Engineering from Duke University. Mr. Mastrototaro has authored over 50 peer reviewed manuscripts and holds over 60 US patents. - John Mastrototaro自2020年12月起担任公司董事,并同意不迟于2021年4月1日成为我们的总裁兼首席执行官。Mastrototaro先生在医疗器械行业拥有超过30年的经验,领导创新并将新产品推向市场。Mastrototaro先生自2017年以来一直担任Orthosensor,Inc.的首席运营官。此前,Mastrototaro先生在Medtronic,plc.和Minimed,Inc.度过了职业生涯的大部分时间,在那里他在发起和领导糖尿病世界的一系列第一方面发挥了重要作用,包括动态连续血糖监测系统,该传感器增强了胰岛素泵和早期人工胰腺。在加入Orthosensor之前,Mastrototaro先生于2013年至2017年担任美敦力(Medtronic&8217;)的首位信息学副总裁,他在该职位上帮助制定了一项利用数据和分析改善梦百合交付的企业战略。在Medtronic&8217;s Diabetes Division任职期间,Mastrototaro先生担任多个职位,包括CTO,研发与业务发展副总裁和临床研究与健康事务全球副总裁。Mastrototaro先生的职业生涯始于礼来公司(Eli Lilly)。他持有Holy Cross College的数学和物理学士学位,以及Duke University的生物医学工程硕士和博士学位。Mastrototaro先生撰写了超过50篇同行评议的手稿,并拥有超过60项美国专利。
- John Mastrototaro has served as Chief Operating Officer of the Company since March 30, 2026. Previously, Mr. Mastrototaro served as President and CEO from April 2021 to March 30, 2026. Mr. Mastrototaro has over 30 years of experience in the medical device industry, leading innovation and bringing new products to the market. Mr. Mastrototaro served as the Chief Operating Officer of Orthosensor, Inc. from 2017 to March 2021. Previously, Mr. Mastrototaro spent the majority of his career with Medtronic, PLC. and MiniMed, Inc., where he was instrumental in initiating and leading a series of firsts in the world of diabetes, including the ambulatory continuous glucose monitoring system, the sensor augmented insulin pump and the early generations of the artificial pancreas. Prior to joining Orthosensor, Mr. Mastrototaro was Medtronic's first VP of Informatics from 2013 to 2017, a role in which he helped develop a corporate strategy for the use of data and analytics to improve healthcare delivery. During his tenure in Medtronic's Diabetes division, Mr. Mastrototaro held a number of positions, including CTO, VP of R&D and Business Development and Global VP of Clinical Research and Health Affairs. Mr. Mastrototaro started his career with Eli Lilly. He holds a B.A. in Mathematics and Physics from Holy Cross College and M.S. and Ph.D. in Biomedical Engineering from Duke University. Mr. Mastrototaro has authored over 50 peer reviewed manuscripts and holds over 60 US patents.
- Rubén Caballero
-
Ruben Caballero自2019年11月起担任公司董事。自2020年4月以来,卡瓦列罗一直担任微软混合现实部门设备与技术工程企业Vice President,负责监管混合现实、人工智能和其他特殊项目。卡瓦列罗曾于2005年至2019年4月担任苹果工程Vice President,在那里他是iPhone硬件设计团队的创始领导者之一,后来又将自己的职责扩展到iPad、Apple Watch、Macintosh和其他硬件产品。Caballero先生在苹果的高级职位为他提供了建立和扩大全球团队的机会,包括苹果所有产品/生态系统的无线设计和技术团队,包括iPhone,iPad,Mac,AirPods,HomePod和配件。任职Apple公司之前,他曾任职两家初创企业,在那里他曾领导设计无线网络音频组件和设备的创新产品和核心技术。自2019年8月起,卡瓦列罗先生担任ResonantInc.董事会成员Nasdaq:RESN,一家致力于改变移动手机和无线设备射频前端设计和交付方式的公司。Mr.Caballero在Cole Polytechnique de Montr&233;al获得电气工程学士学位,在New Mexico State University获得电气工程硕士学位,在Cole Polytechnique de Montr&233;al获得荣誉博士学位。
Rubén Caballero has served as a director of the Company since November 2019. Since June 2024, Mr. Caballero has served as Chief Engineer and Strategy Officer at Humane Inc. From April 2020 until June 2024, Mr. Caballero served as Microsoft's Corporate Vice President of Devices & Technology Engineering for the Mixed Reality Division, where he oversaw Mixed Reality, AI and other special projects. Mr. Caballero served as a Vice President of Engineering at Apple from 2005 until April 2019, where he was one of the founding leaders of the iPhone hardware design team and later expanded his role to include iPad, Apple Watch, Macintosh, and other hardware products. Mr. Caballero's senior role at Apple provided him with the opportunity to build and scale global teams, including the Wireless Design and Technology team for all the products/ecosystems at Apple, including the iPhone, iPad, Macs, AirPods, HomePod, and accessories. Before Apple, Mr. Caballero worked at two start ups, where he led efforts for designing innovative products and core technology for wireless networked audio components and devices. Since August 2019, Mr. Caballero has served as a member of the board of directors of Resonant Inc. (Nasdaq: RESN), a company that is working to transform the way radio frequency, or RF, front ends are being designed and delivered for mobile handset and wireless devices. Mr. Caballero received a Bachelor's degree in Electrical Engineering from cole Polytechnique de Montréal, a Master's degree in Electrical Engineering from New Mexico State University and an Honorary Doctorate from cole Polytechnique de Montréal. - Ruben Caballero自2019年11月起担任公司董事。自2020年4月以来,卡瓦列罗一直担任微软混合现实部门设备与技术工程企业Vice President,负责监管混合现实、人工智能和其他特殊项目。卡瓦列罗曾于2005年至2019年4月担任苹果工程Vice President,在那里他是iPhone硬件设计团队的创始领导者之一,后来又将自己的职责扩展到iPad、Apple Watch、Macintosh和其他硬件产品。Caballero先生在苹果的高级职位为他提供了建立和扩大全球团队的机会,包括苹果所有产品/生态系统的无线设计和技术团队,包括iPhone,iPad,Mac,AirPods,HomePod和配件。任职Apple公司之前,他曾任职两家初创企业,在那里他曾领导设计无线网络音频组件和设备的创新产品和核心技术。自2019年8月起,卡瓦列罗先生担任ResonantInc.董事会成员Nasdaq:RESN,一家致力于改变移动手机和无线设备射频前端设计和交付方式的公司。Mr.Caballero在Cole Polytechnique de Montr&233;al获得电气工程学士学位,在New Mexico State University获得电气工程硕士学位,在Cole Polytechnique de Montr&233;al获得荣誉博士学位。
- Rubén Caballero has served as a director of the Company since November 2019. Since June 2024, Mr. Caballero has served as Chief Engineer and Strategy Officer at Humane Inc. From April 2020 until June 2024, Mr. Caballero served as Microsoft's Corporate Vice President of Devices & Technology Engineering for the Mixed Reality Division, where he oversaw Mixed Reality, AI and other special projects. Mr. Caballero served as a Vice President of Engineering at Apple from 2005 until April 2019, where he was one of the founding leaders of the iPhone hardware design team and later expanded his role to include iPad, Apple Watch, Macintosh, and other hardware products. Mr. Caballero's senior role at Apple provided him with the opportunity to build and scale global teams, including the Wireless Design and Technology team for all the products/ecosystems at Apple, including the iPhone, iPad, Macs, AirPods, HomePod, and accessories. Before Apple, Mr. Caballero worked at two start ups, where he led efforts for designing innovative products and core technology for wireless networked audio components and devices. Since August 2019, Mr. Caballero has served as a member of the board of directors of Resonant Inc. (Nasdaq: RESN), a company that is working to transform the way radio frequency, or RF, front ends are being designed and delivered for mobile handset and wireless devices. Mr. Caballero received a Bachelor's degree in Electrical Engineering from cole Polytechnique de Montréal, a Master's degree in Electrical Engineering from New Mexico State University and an Honorary Doctorate from cole Polytechnique de Montréal.
- Brian Cullinan
-
Brian Cullinan自2020年8月起担任公司董事。Cullinan先生于1997年7月至2020年6月担任普华永道会计师事务所(PricewaterhouseCoopers LLP“;PWC”;)的合伙人。在普华永道(PwC)时,Cullinan先生担任高级关系和全球业务合作伙伴,负责众多普华永道财富500强客户。此外,他曾于2010年至2018年在普华永道会计师事务所(PwC&8217;S)美国合伙人和负责人董事会任职,包括2012年至2016年担任两届首席董事。Cullinan先生于2013年至2017年同时担任普华永道全球董事会成员,并于2011年至2017年担任西南地区管理合伙人。Cullinan先生在普华永道(PwC)的职业生涯中担任过许多其他领导职务,包括从2009年到2012年担任西部地区保证领导者,从2007年到2009年担任美国娱乐,媒体和通信保证领导者。他在康奈尔大学(Cornell University)获得文学学士学位,在东北大学(Northeastern University)获得财务会计理学硕士学位。
Brian Cullinan has served as a director of the Company since August 2020. Mr. Cullinan was a partner at PricewaterhouseCoopers LLP ("PwC") from July 1997 through June 2020. While at PwC, Mr. Cullinan served as a Senior Relationship and Global Engagement Partner with responsibility for numerous PwC Fortune 500 clients. In addition, he served on PwC's U.S. Board of Partners & Principals from 2010 to 2018, including two terms as Lead Director from 2012 to 2016. Mr. Cullinan simultaneously served as a member of PwC's Global Board from 2013 to 2017 and as Managing Partner – Southwest Region from 2011 to 2017. Mr. Cullinan has served in numerous other leadership roles during his career at PwC, including West Region Assurance Leader from 2009 to 2012 and U.S. Entertainment, Media & Communications Assurance Leader from 2007 to 2009. He received a Bachelor of Arts from Cornell University and a Master of Science in Financial Accounting from Northeastern University. - Brian Cullinan自2020年8月起担任公司董事。Cullinan先生于1997年7月至2020年6月担任普华永道会计师事务所(PricewaterhouseCoopers LLP“;PWC”;)的合伙人。在普华永道(PwC)时,Cullinan先生担任高级关系和全球业务合作伙伴,负责众多普华永道财富500强客户。此外,他曾于2010年至2018年在普华永道会计师事务所(PwC&8217;S)美国合伙人和负责人董事会任职,包括2012年至2016年担任两届首席董事。Cullinan先生于2013年至2017年同时担任普华永道全球董事会成员,并于2011年至2017年担任西南地区管理合伙人。Cullinan先生在普华永道(PwC)的职业生涯中担任过许多其他领导职务,包括从2009年到2012年担任西部地区保证领导者,从2007年到2009年担任美国娱乐,媒体和通信保证领导者。他在康奈尔大学(Cornell University)获得文学学士学位,在东北大学(Northeastern University)获得财务会计理学硕士学位。
- Brian Cullinan has served as a director of the Company since August 2020. Mr. Cullinan was a partner at PricewaterhouseCoopers LLP ("PwC") from July 1997 through June 2020. While at PwC, Mr. Cullinan served as a Senior Relationship and Global Engagement Partner with responsibility for numerous PwC Fortune 500 clients. In addition, he served on PwC's U.S. Board of Partners & Principals from 2010 to 2018, including two terms as Lead Director from 2012 to 2016. Mr. Cullinan simultaneously served as a member of PwC's Global Board from 2013 to 2017 and as Managing Partner – Southwest Region from 2011 to 2017. Mr. Cullinan has served in numerous other leadership roles during his career at PwC, including West Region Assurance Leader from 2009 to 2012 and U.S. Entertainment, Media & Communications Assurance Leader from 2007 to 2009. He received a Bachelor of Arts from Cornell University and a Master of Science in Financial Accounting from Northeastern University.
- Emily Wang Fairbairn
-
Emily T.Fairbairn自2021年7月起担任我们的董事会成员。自2018年3月以来,Fairbairn女士一直担任MovanoInc.(一家专注于健康的技术公司)的董事会成员和主席。Fairbairn女士目前是Transcend Partners的负责人,从1999年到2018年,Fairbairn女士是Ascend Capital的联合创始人兼首席执行官,Ascend Capital是一家数十亿美元的对冲基金,专注于为养老金、捐赠基金和上市公司等机构客户管理资产。在创立Ascend Capital之前,Fairbairn女士为Merrill Lynch的高净值客户管理股票投资组合Fairbairn女士是一位活跃的慈善家,拥有支持教育、体育和医学研究的历史。她也是麻省理工学院沙盒创新基金的资助委员会成员,积极指导企业家。Fairbairn女士在加州州立理工大学波莫纳分校获得化学工程学士学位。
Emily Wang Fairbairn has served as a director of the Company and as Chair of the Board since 2018. Ms. Fairbairn has more than 40 years of experience in institutional asset management, capital markets, and operations. She is the co founder and served as Chief Executive Officer of Ascend Capital, a multi billion dollar institutional hedge fund specializing in long/short equity strategies for global pension funds, endowments, and public entities, a position she held for approximately two decades. Prior to founding Ascend Capital, Ms. Fairbairn managed equity portfolios for high net worth clients at Merrill Lynch, and earlier in her career served as a process engineer and production supervisor at Frito Lay, a subsidiary of PepsiCo, where she gained experience in manufacturing operations, large scale capital projects, and workforce management. Ms. Fairbairn has served as an Independent Director of IN8bio, Inc., a clinical stage biopharmaceutical company focused on γδ T cell therapies for the treatment of cancer, since 2021, and has served as a Funding Board Member of the MIT Sandbox Innovation Fund, which supports early stage technology ventures, since 2017. She also serves as a Board Advisor to Acelab Inc., an AI driven materials platform serving the architecture and design industry. Ms. Fairbairn holds a B.S. in Chemical Engineering from California State Polytechnic University, Pomona. - Emily T.Fairbairn自2021年7月起担任我们的董事会成员。自2018年3月以来,Fairbairn女士一直担任MovanoInc.(一家专注于健康的技术公司)的董事会成员和主席。Fairbairn女士目前是Transcend Partners的负责人,从1999年到2018年,Fairbairn女士是Ascend Capital的联合创始人兼首席执行官,Ascend Capital是一家数十亿美元的对冲基金,专注于为养老金、捐赠基金和上市公司等机构客户管理资产。在创立Ascend Capital之前,Fairbairn女士为Merrill Lynch的高净值客户管理股票投资组合Fairbairn女士是一位活跃的慈善家,拥有支持教育、体育和医学研究的历史。她也是麻省理工学院沙盒创新基金的资助委员会成员,积极指导企业家。Fairbairn女士在加州州立理工大学波莫纳分校获得化学工程学士学位。
- Emily Wang Fairbairn has served as a director of the Company and as Chair of the Board since 2018. Ms. Fairbairn has more than 40 years of experience in institutional asset management, capital markets, and operations. She is the co founder and served as Chief Executive Officer of Ascend Capital, a multi billion dollar institutional hedge fund specializing in long/short equity strategies for global pension funds, endowments, and public entities, a position she held for approximately two decades. Prior to founding Ascend Capital, Ms. Fairbairn managed equity portfolios for high net worth clients at Merrill Lynch, and earlier in her career served as a process engineer and production supervisor at Frito Lay, a subsidiary of PepsiCo, where she gained experience in manufacturing operations, large scale capital projects, and workforce management. Ms. Fairbairn has served as an Independent Director of IN8bio, Inc., a clinical stage biopharmaceutical company focused on γδ T cell therapies for the treatment of cancer, since 2021, and has served as a Funding Board Member of the MIT Sandbox Innovation Fund, which supports early stage technology ventures, since 2017. She also serves as a Board Advisor to Acelab Inc., an AI driven materials platform serving the architecture and design industry. Ms. Fairbairn holds a B.S. in Chemical Engineering from California State Polytechnic University, Pomona.
- Seth Demsey
-
Seth Demsey自2024年10月起担任Corvex的联合首席执行官和联合创始人,并担任Corvex董事会成员。在共同创立Corvex之前,Demsey先生于2021年5月至2024年10月期间担任面向工程团队的内部开发者门户configure8的共同创始人。在此之前,Demsey先生于2017年11月至2022年11月担任Clean.io(现为HUMAN Security,Inc.)的联合创始人和顾问,这是一家专注于防范恶意广告和电子商务欺诈的数字安全平台。Demsey先生自2016年11月起担任SalesIntel.io的董事会成员,SalesIntel.io是一个用于销售和营销数据的信号第一管道生成平台,并自2024年4月起担任VWD.ai的战略顾问,该平台是一个用于品牌安全和创作者监控的AI pore平台。Demsey先生获得了巴克内尔大学计算机工程学理学学士学位,并且是宾夕法尼亚大学沃顿商学院的高级研究员。
Seth Demsey has served as a member of the Board since March 19, 2026. Mr. Demsey has served as the Co Chief Executive Officer and Co Founder of Corvex Legacy Holdings, Inc., a wholly owned subsidiary of the Company ("Corvex OpCo") and on the Corvex OpCo board of directors since October 2024. Before joining Corvex OpCo, Mr. Demsey served as the chief executive officer and co founder of Configure8 from May 2021 through October 2024. He has spent nearly three decades architecting and operating high impact AI/ML and developer platforms across startups and industry leaders including NASA, Microsoft, Google, and AOL/Yahoo!. He holds dozens of patents spanning high performance computing, distributed systems, security, and data management. Prior to co founding Corvex, Mr. Demsey served in technical leadership roles driving innovation in large scale distributed computing and mission critical infrastructure. His expertise encompasses the full stack of cloud infrastructure technologies required to deliver reliable, high performance AI computing at scale. Mr. Demsey received a Bachelor of Science degree in Computer Engineering from Bucknell University and was previously a business fellow at The Wharton School of the University of Pennsylvania. - Seth Demsey自2024年10月起担任Corvex的联合首席执行官和联合创始人,并担任Corvex董事会成员。在共同创立Corvex之前,Demsey先生于2021年5月至2024年10月期间担任面向工程团队的内部开发者门户configure8的共同创始人。在此之前,Demsey先生于2017年11月至2022年11月担任Clean.io(现为HUMAN Security,Inc.)的联合创始人和顾问,这是一家专注于防范恶意广告和电子商务欺诈的数字安全平台。Demsey先生自2016年11月起担任SalesIntel.io的董事会成员,SalesIntel.io是一个用于销售和营销数据的信号第一管道生成平台,并自2024年4月起担任VWD.ai的战略顾问,该平台是一个用于品牌安全和创作者监控的AI pore平台。Demsey先生获得了巴克内尔大学计算机工程学理学学士学位,并且是宾夕法尼亚大学沃顿商学院的高级研究员。
- Seth Demsey has served as a member of the Board since March 19, 2026. Mr. Demsey has served as the Co Chief Executive Officer and Co Founder of Corvex Legacy Holdings, Inc., a wholly owned subsidiary of the Company ("Corvex OpCo") and on the Corvex OpCo board of directors since October 2024. Before joining Corvex OpCo, Mr. Demsey served as the chief executive officer and co founder of Configure8 from May 2021 through October 2024. He has spent nearly three decades architecting and operating high impact AI/ML and developer platforms across startups and industry leaders including NASA, Microsoft, Google, and AOL/Yahoo!. He holds dozens of patents spanning high performance computing, distributed systems, security, and data management. Prior to co founding Corvex, Mr. Demsey served in technical leadership roles driving innovation in large scale distributed computing and mission critical infrastructure. His expertise encompasses the full stack of cloud infrastructure technologies required to deliver reliable, high performance AI computing at scale. Mr. Demsey received a Bachelor of Science degree in Computer Engineering from Bucknell University and was previously a business fellow at The Wharton School of the University of Pennsylvania.
高管简历
中英对照 |  中文 |  英文- John Mastrototaro
John Mastrototaro自2020年12月起担任公司董事,并同意不迟于2021年4月1日成为我们的总裁兼首席执行官。Mastrototaro先生在医疗器械行业拥有超过30年的经验,领导创新并将新产品推向市场。Mastrototaro先生自2017年以来一直担任Orthosensor,Inc.的首席运营官。此前,Mastrototaro先生在Medtronic,plc.和Minimed,Inc.度过了职业生涯的大部分时间,在那里他在发起和领导糖尿病世界的一系列第一方面发挥了重要作用,包括动态连续血糖监测系统,该传感器增强了胰岛素泵和早期人工胰腺。在加入Orthosensor之前,Mastrototaro先生于2013年至2017年担任美敦力(Medtronic&8217;)的首位信息学副总裁,他在该职位上帮助制定了一项利用数据和分析改善梦百合交付的企业战略。在Medtronic&8217;s Diabetes Division任职期间,Mastrototaro先生担任多个职位,包括CTO,研发与业务发展副总裁和临床研究与健康事务全球副总裁。Mastrototaro先生的职业生涯始于礼来公司(Eli Lilly)。他持有Holy Cross College的数学和物理学士学位,以及Duke University的生物医学工程硕士和博士学位。Mastrototaro先生撰写了超过50篇同行评议的手稿,并拥有超过60项美国专利。
John Mastrototaro has served as Chief Operating Officer of the Company since March 30, 2026. Previously, Mr. Mastrototaro served as President and CEO from April 2021 to March 30, 2026. Mr. Mastrototaro has over 30 years of experience in the medical device industry, leading innovation and bringing new products to the market. Mr. Mastrototaro served as the Chief Operating Officer of Orthosensor, Inc. from 2017 to March 2021. Previously, Mr. Mastrototaro spent the majority of his career with Medtronic, PLC. and MiniMed, Inc., where he was instrumental in initiating and leading a series of firsts in the world of diabetes, including the ambulatory continuous glucose monitoring system, the sensor augmented insulin pump and the early generations of the artificial pancreas. Prior to joining Orthosensor, Mr. Mastrototaro was Medtronic's first VP of Informatics from 2013 to 2017, a role in which he helped develop a corporate strategy for the use of data and analytics to improve healthcare delivery. During his tenure in Medtronic's Diabetes division, Mr. Mastrototaro held a number of positions, including CTO, VP of R&D and Business Development and Global VP of Clinical Research and Health Affairs. Mr. Mastrototaro started his career with Eli Lilly. He holds a B.A. in Mathematics and Physics from Holy Cross College and M.S. and Ph.D. in Biomedical Engineering from Duke University. Mr. Mastrototaro has authored over 50 peer reviewed manuscripts and holds over 60 US patents.- John Mastrototaro自2020年12月起担任公司董事,并同意不迟于2021年4月1日成为我们的总裁兼首席执行官。Mastrototaro先生在医疗器械行业拥有超过30年的经验,领导创新并将新产品推向市场。Mastrototaro先生自2017年以来一直担任Orthosensor,Inc.的首席运营官。此前,Mastrototaro先生在Medtronic,plc.和Minimed,Inc.度过了职业生涯的大部分时间,在那里他在发起和领导糖尿病世界的一系列第一方面发挥了重要作用,包括动态连续血糖监测系统,该传感器增强了胰岛素泵和早期人工胰腺。在加入Orthosensor之前,Mastrototaro先生于2013年至2017年担任美敦力(Medtronic&8217;)的首位信息学副总裁,他在该职位上帮助制定了一项利用数据和分析改善梦百合交付的企业战略。在Medtronic&8217;s Diabetes Division任职期间,Mastrototaro先生担任多个职位,包括CTO,研发与业务发展副总裁和临床研究与健康事务全球副总裁。Mastrototaro先生的职业生涯始于礼来公司(Eli Lilly)。他持有Holy Cross College的数学和物理学士学位,以及Duke University的生物医学工程硕士和博士学位。Mastrototaro先生撰写了超过50篇同行评议的手稿,并拥有超过60项美国专利。
- John Mastrototaro has served as Chief Operating Officer of the Company since March 30, 2026. Previously, Mr. Mastrototaro served as President and CEO from April 2021 to March 30, 2026. Mr. Mastrototaro has over 30 years of experience in the medical device industry, leading innovation and bringing new products to the market. Mr. Mastrototaro served as the Chief Operating Officer of Orthosensor, Inc. from 2017 to March 2021. Previously, Mr. Mastrototaro spent the majority of his career with Medtronic, PLC. and MiniMed, Inc., where he was instrumental in initiating and leading a series of firsts in the world of diabetes, including the ambulatory continuous glucose monitoring system, the sensor augmented insulin pump and the early generations of the artificial pancreas. Prior to joining Orthosensor, Mr. Mastrototaro was Medtronic's first VP of Informatics from 2013 to 2017, a role in which he helped develop a corporate strategy for the use of data and analytics to improve healthcare delivery. During his tenure in Medtronic's Diabetes division, Mr. Mastrototaro held a number of positions, including CTO, VP of R&D and Business Development and Global VP of Clinical Research and Health Affairs. Mr. Mastrototaro started his career with Eli Lilly. He holds a B.A. in Mathematics and Physics from Holy Cross College and M.S. and Ph.D. in Biomedical Engineering from Duke University. Mr. Mastrototaro has authored over 50 peer reviewed manuscripts and holds over 60 US patents.
- Jeremy Cogan
Jeremy Cogan自2019年5月起担任公司首席财务官。从2007年7月至2018年12月,Cogan先生管理Ascend Capital的休闲与媒体投资组合,Ascend Capital是一家位于旧金山湾区的数十亿美元的多头/空头股票对冲基金。在Ascend,他也是公司执行委员会的成员。Cogan从1995年1月到2007年5月担任Banc of America Securities LLC及其前身股票研究团队成员。在Banc of America Securities任职的大部分时间里,Cogan先生是首席和高级股票研究分析师,负责博彩和住宿部门。Cogan先生在宾夕法尼亚大学(University of Pennsylvania)获得传播学文学学士学位,并自2000年9月起担任特许金融分析师(CFA)特许持有人。
Jeremy Cogan has served as the Company's Chief Financial Officer since May 2019. Mr. Cogan has 30 years of financial experience to the Company. From July 2007 to December 2018, Mr. Cogan managed the Leisure & Media portfolio at Ascend Capital, a multi billion dollar, long/short equity hedge fund, based in the San Francisco Bay Area. At Ascend, he was also a member of the firm's Executive Committee. From January 1995 to May 2007, Mr. Cogan was a member of the equity research team at Banc of America Securities LLC (and its predecessors). For the majority of his tenure at Banc of America Securities, Mr. Cogan was a Principal and Senior Equity Research Analyst, responsible for the Gaming and Lodging sectors. Mr. Cogan received a Bachelor of Arts degree in Communications from the University of Pennsylvania.- Jeremy Cogan自2019年5月起担任公司首席财务官。从2007年7月至2018年12月,Cogan先生管理Ascend Capital的休闲与媒体投资组合,Ascend Capital是一家位于旧金山湾区的数十亿美元的多头/空头股票对冲基金。在Ascend,他也是公司执行委员会的成员。Cogan从1995年1月到2007年5月担任Banc of America Securities LLC及其前身股票研究团队成员。在Banc of America Securities任职的大部分时间里,Cogan先生是首席和高级股票研究分析师,负责博彩和住宿部门。Cogan先生在宾夕法尼亚大学(University of Pennsylvania)获得传播学文学学士学位,并自2000年9月起担任特许金融分析师(CFA)特许持有人。
- Jeremy Cogan has served as the Company's Chief Financial Officer since May 2019. Mr. Cogan has 30 years of financial experience to the Company. From July 2007 to December 2018, Mr. Cogan managed the Leisure & Media portfolio at Ascend Capital, a multi billion dollar, long/short equity hedge fund, based in the San Francisco Bay Area. At Ascend, he was also a member of the firm's Executive Committee. From January 1995 to May 2007, Mr. Cogan was a member of the equity research team at Banc of America Securities LLC (and its predecessors). For the majority of his tenure at Banc of America Securities, Mr. Cogan was a Principal and Senior Equity Research Analyst, responsible for the Gaming and Lodging sectors. Mr. Cogan received a Bachelor of Arts degree in Communications from the University of Pennsylvania.
- Jay Crystal
Jay Crystal自2024年10月起担任Corvex的联合首席执行官和联合创始人,并担任Corvex董事会成员。在共同创立Corvex之前,Crystal先生于2021年5月至2024年10月担任configure8的共同创始人。在此之前,Crystal先生于2017年11月至2022年11月期间担任Clean.io(现为HUMAN Security,Inc.)的联合创始人和董事。Crystal先生还曾在AOL,Inc.及其继任者和子公司担任多个管理职务,包括2010年至2017年担任企业发展董事和企业战略副总裁、合伙企业以及多家投资银行、私募股权和全球资产管理公司,包括2000年至2010年的Staley Capital、美国资本和美国银行。Crystal先生获得了乔治华盛顿学金融学学士学位。
Jay Crystal has served as the Chief Executive Officer of the Company since March 31, 2026. Mr. Crystal has served as the Co Chief Executive Officer and Co Founder of Corvex OpCo and on the Corvex OpCo board of directors since October 2024. Prior to co founding Corvex OpCo, Mr. Crystal previously co founded and served as a board director of clean.io (now HUMAN Security, Inc.) and configure8. Mr. Crystal also served in several management roles at AOL, Inc. and its successors and subsidiaries, including as Director, Corporate Development and Vice President, Corporate Strategy and Partnerships, from 2010 to 2017. Mr. Crystal began his career serving in growth equity, private equity, and investment banking roles at Staley Capital, American Capital and Banc of America Securities between 2000 to 2010.- Jay Crystal自2024年10月起担任Corvex的联合首席执行官和联合创始人,并担任Corvex董事会成员。在共同创立Corvex之前,Crystal先生于2021年5月至2024年10月担任configure8的共同创始人。在此之前,Crystal先生于2017年11月至2022年11月期间担任Clean.io(现为HUMAN Security,Inc.)的联合创始人和董事。Crystal先生还曾在AOL,Inc.及其继任者和子公司担任多个管理职务,包括2010年至2017年担任企业发展董事和企业战略副总裁、合伙企业以及多家投资银行、私募股权和全球资产管理公司,包括2000年至2010年的Staley Capital、美国资本和美国银行。Crystal先生获得了乔治华盛顿学金融学学士学位。
- Jay Crystal has served as the Chief Executive Officer of the Company since March 31, 2026. Mr. Crystal has served as the Co Chief Executive Officer and Co Founder of Corvex OpCo and on the Corvex OpCo board of directors since October 2024. Prior to co founding Corvex OpCo, Mr. Crystal previously co founded and served as a board director of clean.io (now HUMAN Security, Inc.) and configure8. Mr. Crystal also served in several management roles at AOL, Inc. and its successors and subsidiaries, including as Director, Corporate Development and Vice President, Corporate Strategy and Partnerships, from 2010 to 2017. Mr. Crystal began his career serving in growth equity, private equity, and investment banking roles at Staley Capital, American Capital and Banc of America Securities between 2000 to 2010.